Moderna, BioNtech surge as COVID-19 vaccine development progresses amid virus spike
Carol Smiljan/NurPhoto via Getty Images
- Moderna and BioNtech surged in Thursday trades amid updates on the development of a COVID-19 vaccine.
- Investor focus on a potential vaccine is heightened as daily COVID-19 cases spike across the US and in Europe.
- Moderna said it’s “actively preparing for the launch” of its COVID-19 vaccine, while a report from the Wall Street Journal said Germany could begin vaccinations this year with a BioNtech vaccine.
- Visit the Business Insider homepage for more stories.
Moderna and BioNtech surged in Thursday trades as investor focus on a successful COVID-19 vaccine remained heightened amid a surge in daily virus cases.
Moderna traded higher by as much as 13%, while BioNtech jumped as much as 11%.
In its third quarter earnings report, Moderna said it’s “actively preparing for the launch” of its COVID-19 vaccine.
Moderna’s phase III trial of the vaccine candidate is fully enrolled with 30,000 patients.
To date, Moderna has received more than $1 billion in deposits from governments around the world who are eager to distribute a successful COVID-19 vaccine.
The most recent deal struck by Moderna was with Takeda of Japan, announced earlier today. Moderna will supply Takeda with 50 million doses of its COVID-19 vaccine in the first half of 2021 pending approval in Japan.
Depending on the results of a clinical trial, BioNtech’s COVID-19 vaccine could be rapidly distributed across Germany by the end of this year, The Wall Street Journal reported on Thursday.
Read more: BANK OF AMERICA: Buy these 6 food stocks best-positioned for stay-at-home Halloween celebrations as towns curb trick-or-treating
According to people familiar with the strategy, a plan is in place for doses of the BioNtech vaccine to be shipped to more than 60 regional vaccine centers in Germany within hours of approval.
Initial recipients of a successful COVID vaccine in Germany would include health-care workers, the elderly, and clinically vulnerable people, among others.
BioNtech has partnered with Pfizer on the development of a COVID-19 vaccine and it hopes to submit its vaccine for authorization in November.
BioNtech and Pfizer have already produced millions of doses of its vaccine so it can deliver on pre-purchasing contracts, according to The Wall Street Journal.
A vaccine couldn’t come soon enough. The US has experienced record daily virus cases this past weekend, and new lockdown measures have hit Germany and France as they attempt to contain a resurgence of the virus.
Read More: Here’s the 6 killer pieces of advice for trading European stocks after the US election, from investment giants UBS and Barclays
Source: Read Full Article